Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBUS-TBNI Cisplatin for Stage IV Lung Cancer
NCT04311762Phase 1Active, not recruiting
- Sponsor
- The University of Vermont
- Start
- Feb 2020
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cisplatin in non-small cell lung cancer (NSCLC), sponsored by The University of Vermont. Primary endpoint: Dose Limiting Toxicity at 14 days. Started Feb 2020; status: active, not recruiting.
02
Drugs
cisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04311762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04311762.